The promising results from the clinical study on Organigram's nanoemulsion technology, FAST, indicate potential for significant advancements in their cannabis edibles products. The faster onset and improved bioavailability could attract more consumers, boosting sales and revenues. The planned commercialization in fall 2024 further supports a positive short-term impact on the stock price.